The lidERA Breast Cancer study is a phase 3, randomized, open-label trial testing whether the adjuvant therapy giredestrant ...

A research group led by Assistant Professor Megumi Aimoto and Professor Akira Takahara at the Faculty of Pharmaceutical ...

Researchers from The University of Texas at Dallas' Center for Advanced Pain Studies (CAPS) and their colleagues have made a ...

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) use was significantly associated with a reduced odds of five-year mortality, but this protective effect was found to be statistically significant ...

A study in the Journal of Investigative Dermatology suggested that using a cannabinoid receptor type 2 (CB2) agonist called lenabasum may lessen the discomfort caused by amyopathic dermatomyositis.

CAR-T cell therapy has emerged as a transformative approach in treating B cell malignancies and multiple myeloma. However, this approach is in desperate need of refinement. While attacking tumor cells ...

GLP-1 RAs are associated with a 62% reduction in 5-year mortality in colon cancer patients, especially those with high obesity. The study's findings remained significant after adjusting for ...

Giredestrant significantly improves IDFS in ER-positive, HER2-negative early-stage breast cancer, surpassing standard ...

Tirzepatide, semaglutide, and liraglutide lead to weight loss in adults with obesity and T1D over 1 year; the greatest weight ...

Surprisingly, bitter taste receptors are not only located in the mouth, but also elsewhere in the body, including the airways. Activating those receptors opens up lung passageways, so they're a ...